CSIMarket
 


Bioxcel Therapeutics Inc   (BTAI)
Other Ticker:  
 

Bioxcel Therapeutics Inc 's Working Capital Ratio

BTAI's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Current Liabilities decreased faster than Bioxcel Therapeutics Inc 's Current Assets, this led to improvement in Bioxcel Therapeutics Inc 's Working Capital Ratio to 2.65, Working Capital Ratio remained below Bioxcel Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 142 other companies have achieved higher Working Capital Ratio than Bioxcel Therapeutics Inc in forth quarter 2023. While Working Capital Ratio total ranking has improved so far during the IV Quarter 2023 to 1002, from total ranking in the third quarter 2023 at 1778.

Explain Working Capital Ratio
How much in Current Assets BTAI´s has?
What is the value of BTAI´s Current Liabilities?


BTAI Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -17.12 % 68.57 % 73.76 % 79.78 % 97.38 %
Y / Y Current Assets Change -64.44 % -59.14 % -43.56 % -14.6 % -14.33 %
Working Capital Ratio MRQ 2.65 2.51 3.98 6.16 6.17
BTAI's Total Ranking # 1002 # 1778 # 1175 # 658 # 822
Seq. Current Liabilities Change -30.81 % 13.42 % 20.81 % -12.58 % 40.72 %
Seq. Current Assets Change -26.93 % -28.57 % -22.02 % -12.62 % -16.05 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 143
Healthcare Sector # 294
Overall Market # 1002


Working Capital Ratio Statistics
High Average Low
22.24 9.55 2.51
(Jun 30 2021)   (Sep 30 2023)




Financial Statements
Bioxcel Therapeutics Inc 's Current Liabilities $ 27 Millions Visit BTAI's Balance sheet
Bioxcel Therapeutics Inc 's Current Assets $ 72 Millions Visit BTAI's Balance sheet
Source of BTAI's Sales Visit BTAI's Sales by Geography


Cumulative Bioxcel Therapeutics Inc 's Working Capital Ratio

BTAI's Working Capital Ratio for the trailling 12 Months

BTAI Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -17.12 % 68.57 % 73.76 % 79.78 % 97.38 %
Y / Y Current Assets TTM Growth -64.44 % -59.14 % -43.56 % -14.6 % -14.33 %
Working Capital Ratio TTM 3.74 4.54 6.35 8.25 9.72
Total Ranking TTM # 2368 # 3871 # 877 # 2786 # 172
Seq. Current Liabilities TTM Growth -30.81 % 13.42 % 20.81 % -12.58 % 40.72 %
Seq. Current Assets TTM Growth -26.93 % -28.57 % -22.02 % -12.62 % -16.05 %


On the trailing twelve months basis In spite of the year on year decrease in BTAI's Current Liabilities to $27.27 millions, cumulative Working Capital Ratio to 3.74 below the BTAI average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 209 other companies have achieved higher Working Capital Ratio than Bioxcel Therapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 2368, from total ranking during the twelve months ending third quarter 2023 at 3871.

Explain Working Capital Ratio
How much in Current Assets BTAI´s has?
What is the value of BTAI´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 210
Healthcare Sector # 479
Within the Market # 2368


trailing twelve months Working Capital Ratio Statistics
High Average Low
17.5 9.99 3.74
(Jun 30 2021)   (Dec 31 2023)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Kronos Bio Inc   7.24 $ 178.778  Millions$ 24.695  Millions
Siga Technologies Inc  7.17 $ 238.991  Millions$ 33.329  Millions
Zentalis Pharmaceuticals Inc   7.16 $ 496.718  Millions$ 69.367  Millions
Werewolf Therapeutics Inc   7.14 $ 138.370  Millions$ 19.378  Millions
Arcutis Biotherapeutics Inc   7.08 $ 330.431  Millions$ 46.668  Millions
Harmony Biosciences Holdings inc   7.02 $ 451.070  Millions$ 64.287  Millions
Generation Bio Co   6.83 $ 272.618  Millions$ 39.914  Millions
Anebulo Pharmaceuticals Inc   6.73 $ 6.816  Millions$ 1.014  Millions
Incannex Healthcare Inc   6.70 $ 21.332  Millions$ 3.186  Millions
Ocular Therapeutix Inc   6.66 $ 232.235  Millions$ 34.896  Millions
Regeneron Pharmaceuticals Inc   6.57 $ 19,479.200  Millions$ 2,964.500  Millions
Inflarx N v   6.50 $ 122.605  Millions$ 18.866  Millions
Glycomimetics Inc   6.41 $ 43.791  Millions$ 6.835  Millions
Tharimmune Inc   6.03 $ 10.946  Millions$ 1.815  Millions
Gossamer Bio Inc   5.94 $ 306.519  Millions$ 51.598  Millions
Lumos Pharma Inc   5.93 $ 40.035  Millions$ 6.748  Millions
Ionis Pharmaceuticals Inc  5.90 $ 2,641.853  Millions$ 448.090  Millions
Leap Therapeutics inc   5.76 $ 71.597  Millions$ 12.422  Millions
Lexicon Pharmaceuticals Inc   5.60 $ 176.547  Millions$ 31.546  Millions
Nanoviricides inc   5.59 $ 5.318  Millions$ 0.951  Millions
Marker Therapeutics inc   5.57 $ 17.127  Millions$ 3.075  Millions
Aurinia Pharmaceuticals Inc   5.50 $ 424.800  Millions$ 77.188  Millions
Verastem inc   5.45 $ 143.682  Millions$ 26.380  Millions
Urogen Pharma Ltd   5.42 $ 169.186  Millions$ 31.212  Millions
Intra cellular Therapies Inc   5.41 $ 667.799  Millions$ 123.545  Millions
Madrigal Pharmaceuticals Inc   5.40 $ 637.281  Millions$ 118.021  Millions
Praxis Precision Medicines Inc   5.39 $ 84.880  Millions$ 15.749  Millions
Indaptus Therapeutics Inc   5.24 $ 13.995  Millions$ 2.672  Millions
Phibro Animal Health Corporation  5.22 $ 586.586  Millions$ 112.455  Millions
Legend Biotech Corporation  5.19 $ 1,497.799  Millions$ 288.531  Millions

Date modified: 2024-03-23T15:04:49+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com